Skip to main content
. 2012 Jul;181(1):196–210. doi: 10.1016/j.ajpath.2012.03.018

Figure 1.

Figure 1

Administration of VLPs protects against MRSA pneumonia. A and B: Female BALB/c mice are nasally dosed five times every other day over 2 weeks (arrow) with PCN or PBS. One week after the last dose, mice are challenged with MRSA. C and D: Mice are infected with MRSA and then treated with PCN or PBS three times: 1, 7, and 19 hours after infection. A and C: The bacterial burden in lungs is determined 72 hours after infection. B and D: The survival of mice is monitored daily. Each experiment is repeated three times. The mean ± SD from 9 to 15 mice per group (representing three combined independent experiments) is shown. **P < 0.01, ***P < 0.001 versus PCN-dosed mice.